drugset
Drugs / GV20-0251
last change Jun 2026 re-read 2 minutes ago

GV20-0251

Monoclonal antibody targets IGSF8 via inhibition

Developed for
head and neck squamous cell carcinoma · non-small cell lung carcinoma · cholangiocarcinoma · colorectal adenocarcinoma · endometrial carcinoma · hepatocellular carcinoma · melanoma · pancreatic ductal adenocarcinoma
+13 more · refractory malignant neoplasm · small cell lung carcinoma · cervical cancer · colorectal neoplasm · cutaneous melanoma · endometrial cancer · esophageal squamous cell carcinoma · gallbladder neoplasm · high grade malignant neoplasm · metastatic neoplasm · prostate neoplasm · testicular cancer · triple-negative breast carcinoma
Investigated by
GV20 Therapeutics · West China Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Merck Sharp & Dohme LLC

Trials 6 · a red edge is where a trial was stopped

today NCT07623642 · Ph 2 NCT07457281 · Ph 1 NCT07307053 · Ph 1/2 NCT07106827 · Ph 1 NCT07070518 · Ph 1/2 NCT05669430 · Ph 1/2
202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07457281 Apr 2026 → Apr 2027 expected head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT07106827 Sep 2025 → Jun 2027 expected cholangiocarcinoma, endometrial cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 West China Hospital Recruiting No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07307053 Jan 2026 → Jan 2029 expected high grade malignant neoplasm, metastatic neoplasm Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1/2 NCT07070518 Jul 2025 → Jul 2027 expected colorectal adenocarcinoma, endometrial carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 GV20 Therapeutics Recruiting No outcome recorded
Phase 1/2 NCT05669430 Mar 2023 → Dec 2026 expected colorectal adenocarcinoma, cutaneous melanoma, endometrial carcinoma, head and neck squamous cell carcinoma +2 GV20 Therapeutics Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07623642 Jun 2026 → Jun 2028 expected cervical cancer, cholangiocarcinoma, colorectal neoplasm, esophageal squamous cell carcinoma +7 GV20 Therapeutics Not yet recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as GV20-0251 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07457281 ↗
5

NCT07623642 ↗

NCT07307053 ↗

NCT07106827 ↗

NCT07070518 ↗

NCT05669430 ↗
Action Inhibit “it blocks the interaction between IGSF8 and its receptors on NK and DC cells” NCT07307053 ↗
Modality Monoclonal antibody “monoclonal antibody” NCT07307053 ↗
Route Intravenous “GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks” NCT05669430 ↗
Target IGSF8 “targeting the highly conserved immunomodulatory protein IGSF8” NCT07307053 ↗